【New Stock IPO】【Dark Market/Allocation Results】The biopharmaceutical company ALEBUND-B (9637), which provides kidney dis…
I'm LongbridgeAI, I can summarize articles.ALEBUND-B performed strongly in the dark market, with the Bright Smart platform rising by 94.159% to HKD 43.88, resulting in a paper profit of HKD 2,128 for one lot. The company will officially list next Monday, with an offering price of HKD 22.6, raising HKD 1.28 billion
The biopharmaceutical company ALEBUND-B (9637.HK), which provides treatments for kidney disease, will officially list next Monday (29th), with dark trading taking place today (26th). Among the three major trading platforms, the dark trading performed best on Huatai, reaching HKD 43.88, nearly 94.159% higher than the offering price of HKD 22.6. A single lot of 100 shares yields a paper profit of HKD 2,128.
| Dark Trading Platform | Latest Dark Price (HKD) |
Change % | Transaction Amount (HKD) |
| Huatai | 43.88 | 94.159% | 83.7 million |
| Futu | 42.5 | 88.05% | 150 million |
| YaoCai | 42.18 | 86.64% | 28.3 million |
The biopharmaceutical company ALEBUND-B (9637.HK) conducted its IPO from June 18 to 24, planning to issue 56.755 million H shares, with 10% available for public offering in Hong Kong at an offering price of HKD 22.6, raising HKD 1.28 billion. The entry fee for one lot of 100 shares is HKD 2,282.79. ALEBUND-B is expected to be listed for trading on June 29, with Jefferies, Bank of America Securities, and Huatai International as joint sponsors.
Related information: The biopharmaceutical company ALEBUND (9637) is conducting an IPO, introducing major investors such as Tencent and Singapore's GIC, with an entry fee of HKD 2,282.8. Will you subscribe?
Background
ALEBUND (Jiangsu) Co., Ltd. was established in 2018 and is a biopharmaceutical company providing treatments for kidney disease.
As of June 12, 2026, the group's clinical and preclinical product portfolio consists of one core product, AP301, and six other candidate products, including one late-stage clinical candidate (AP306), one preclinical candidate drug (AP303), and four preclinical candidate drugs (AP308, AP304, AP305, and AP307).
The group's single core product, AP301, is classified as a new drug in China and is a phosphate binder used for treating hyperphosphatemia. AP306 is a differentiated polyphosphate transporter inhibitor for CKD patients undergoing dialysis, used for treating hyperphosphatemia.
As of June 12, 2026, the group holds 153 patents and patent applications, of which 24 are related to the core product. The group has completed the construction of its production base in Yangzhou, China, and its revenue comes from a single customer, which is the distributor of Merck in China